Ardelyx irritable bowel syndrome drug succeeds in mid-stage trial | Reuters
Oct 1 Ardelyx Inc said its experimental
drug to treat constipation-related irritable bowel syndrome
achieved the main goal of increasing bowel movement compared to
a placebo in a mid-stage study involving 371 patients.
Ardelyx licensed the drug, tenapanor, to AstraZeneca Plc
in October 2012.
The companies are also testing the drug for two
(Reporting by Amrutha Penumudi in Bangalore; Editing by Ted
Know more here.